-
The following is an overview of some presentations at the annual meeting of the Society for Healthcare Epidemiology of America.
-
Comparison of 2 meropenem dosing regimens, 500 mg q 6 h and 1000 mg q 8h, found that the resultant pharmacokinetics and pharmacodynamics were equivalent.
-
-
-
-
In one of the more bizarre stories of the year, the FDA has uncovered files of counterfeit Procrit (epoetin alfaJohnson & Johnson) in routine surveillance. To make matters worse, the fake vials have been contaminated with bacteria and many contain no active ingredient.
-
This is the first reported clinical trial of the effects of creatine in sporadic ALS patients. The trial was carried out in The Netherlands.
-
A number of neurotrophic factors have great promise for the treatment of neurologic diseases. Prior work showed that a number of neurotrophic factors appeared to have promise for treating ALS, as well as peripheral neuropathy.
-
Inhibition of thromboxane A2 synthesis by aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) underlies the risk of bleeding complications associated with their use. Aspirin use is associated with a reduced risk of thrombotic events and possibly an increased risk for intracerebral hemorrhage (ICH).
-
Consider this all-too-familiar scenario. Patient X awakens from otherwise uneventful abdominal surgery and complains of ulnar nerve distribution weakness or tingling, or both. Ulnar neuropathy at the elbow (UNE) is documented, litigation ensues, and large sums of money exchange hands. Who is guilty and of what?